Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target boosted by Chardan Capital from $325.00 to $400.00 in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms also recently commented on ALNY. Needham & Company LLC upped their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a “buy” rating in a research report on Thursday. Bank of America raised their price objective on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a “buy” rating in a research note on Friday, July 11th. Wells Fargo & Company raised their price objective on Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the stock an “equal weight” rating in a research note on Monday, June 30th. JPMorgan Chase & Co. raised their price objective on Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 16th. Finally, BMO Capital Markets raised their price objective on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-three have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $392.13.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $401.80 on Friday. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $402.43. The stock’s 50 day moving average is $318.24 and its 200-day moving average is $279.01. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. The company has a market capitalization of $52.67 billion, a price-to-earnings ratio of -162.67 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 444.38%. The firm had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. During the same period in the previous year, the company posted ($0.16) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 20.2% compared to the same quarter last year. Equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the firm’s stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the sale, the chief executive officer owned 48,948 shares of the company’s stock, valued at approximately $14,978,088. This trade represents a 28.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. SVB Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $27,000. Whipplewood Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 69 shares during the last quarter. Park Square Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $28,000. Finally, Ameritas Advisory Services LLC bought a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $42,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.